Tripartite exosome-mRNA vaccine - Capricor Therapeutics
Alternative Names: Exosome-mRNA COVID-2019 vaccine; Exosome-mRNA multivalent SARS-CoV-2 vaccine; Exosome-mRNA vaccine; Exosome-SARS-CoV-2 mRNA Vaccine; Multivalent exosome mRNA vaccineLatest Information Update: 28 Sep 2024
At a glance
- Originator Capricor Therapeutics
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (IM)
- 15 Dec 2023 Capricor terminates the research agreement with John Hopkin's University for Covid-19 infections
- 13 Dec 2021 Pharmacodynamics and adverse events data from preclinical studies in COVID-2019 infections released by Capricor Therapeutics